Loss of PTEN function, which leads to activation of the PI3K/Akt-pathway, is found in about 20% of primary prostate cancers and in about 50% of androgen-independent tumors, indicating that it may also contribute to the acquisition of castration resistance [46,55]. Here, PTEN is linked to prostate carcinoma.